Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Y0000363

Ciprofibrate for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Ciprofibrate, 2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C13H14Cl2O3
CAS Number:
52214-84-3
Molecular Weight:
289.15
MDL number:
MFCD00467135
UNSPSC Code:
41116107
PubChem Substance ID:
329830919
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

ciprofibrate

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC(C)(Oc1ccc(cc1)C2CC2(Cl)Cl)C(O)=O

InChI

1S/C13H14Cl2O3/c1-12(2,11(16)17)18-9-5-3-8(4-6-9)10-7-13(10,14)15/h3-6,10H,7H2,1-2H3,(H,16,17)

InChI key

KPSRODZRAIWAKH-UHFFFAOYSA-N

Gene Information

human ... PPARA(5465)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ciprofibrate for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H350

Precautionary Statements

P201 - P280 - P308 + P313

Hazard Classifications

Carc. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

G Turpin et al.
Atherosclerosis, 124 Suppl, S83-S87 (1996-07-01)
Ciprofibrate is an effective treatment for three main types of atherogenic hyperlipoproteinaemia: type IIa hypercholesterolaemia, type IIb combined hyperlipidaemia, and type IV hypertriglyceridaemia. In type IIa hypercholesterolaemia, administration of 100 mg/day of ciprofibrate, to approximately 3000 patients, decreased total cholesterol
M J Chapman et al.
Atherosclerosis, 124 Suppl, S21-S28 (1996-07-01)
Triglyceride levels greater than 150 mg/dl are associated with the atherogenic lipoprotein phenotype, represented by a predominance of small, dense low density lipoproteins (LDL) and diminished concentrations of high density lipoproteins. This phenotype is characteristic of patients with combined hyperlipidemia
D J Betteridge
Postgraduate medical journal, 69 Suppl 1, S42-S47 (1993-01-01)
The cornerstone of management in hyperlipidaemia is dietary and lifestyle therapy. Nonetheless, a proportion of patients will require drug therapy. Of the currently available choices, statins are of obvious value for raised cholesterol and low dose resins have a place

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service